Daxor (NASDAQ:DXR – Get Free Report) had its price objective raised by investment analysts at Ascendiant Capital Markets from $24.75 to $25.00 in a research note issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Ascendiant Capital Markets’ price target would indicate a potential upside of 205.62% from the company’s previous close.
Daxor Stock Performance
Shares of DXR stock opened at $8.18 on Monday. Daxor has a twelve month low of $6.55 and a twelve month high of $10.00. The business has a fifty day simple moving average of $7.79 and a 200 day simple moving average of $8.49.
Insider Activity
In related news, CEO Michael Richard Feldschuh purchased 3,360 shares of the stock in a transaction dated Monday, March 10th. The stock was bought at an average cost of $7.68 per share, for a total transaction of $25,804.80. Following the completion of the acquisition, the chief executive officer now owns 210,852 shares of the company’s stock, valued at approximately $1,619,343.36. This represents a 1.62 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 59.00% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Daxor
About Daxor
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.
Recommended Stories
- Five stocks we like better than Daxor
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Meta Platforms: Can LLaMA Drive Long-Term Stock Growth?
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- 3 Unique and Dominant Consumer Staples ETF Plays
- Breakout Stocks: What They Are and How to Identify Them
- 3 Dividend Stocks Offering Higher Yields and Bullish Forecasts
Receive News & Ratings for Daxor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor and related companies with MarketBeat.com's FREE daily email newsletter.